Analytical Services - Inhaled Products

Access the delivery technology best suited to the needs of your development programme, including unit-dose and multi-unit dose DPIs, pMDIs and smart nebulisers, suitable for home or hospital applications.

Dry Powder Inhalers:
Options include proprietary unit- and multi-unit dose platforms, as well as off-the-shelf capsule devices, to support your programme from early development through to a commercial-ready device.

Nebulisers:
Our state-of-the-art breath-actuated nebulisers with guided inhalation have been developed to improve lung delivery for inhaled drugs, with the aim of achieving better clinical outcomes and/or shortened treatment times.

Metered Dose Inhalers:
With extensive expertise in pMDI development and lifecycle management, we can help develop a new pMDI product or optimise your existing formulation and device performance. 

With expertise in powder and liquid formulations for small molecules and biologics, as well as a broad portfolio of proprietary device and formulation technologies, we can help you overcome the challenges of inhaled formulation development.

Dry Powder Formulation
Advanced powder blends
Spray-dried, particle engineered formulations
Formulations for non-proprietary capsule devices

Liquid Formulation for Nebulisation
Aqueous solutions and suspensions optimised for smart nebuliser delivery
Freeze-dried powders for reconstitution

Non-Aqueous Liquid Formulation for pMDI
Non-aqueous pressurised solutions and suspensions using HFA propellants
Matched API, formulation and in vitro performance for generic programmes

In addition to extensive development manufacturing facilities, Vectura has GMP manufacturing facilities for dry powder inhalers, pMDI and nebuliser medical devices as well as further capability to handle biological molecules. 

Our GMP manufacturing facilities and equipment are relevant-to-commercial scale, meet all required EHS, Quality and Regulatory standards and are operated by a dedicated manufacturing team.

Our formulation, device and development services are supported by our medical, regulatory, device vigilance and pharmacovigilance teams to safeguard your programme and ensure the smoothest path to product approval.

Our in-house team can support with:

Global regulatory development strategy and submission expertise (NCEs and generics)
Medical devices and combination products including compliance with the EU Medical Device Regulation (MDR)
Global pharmacovigilance and device vigilance capabilities
Clinical strategy and protocol development

Our dry powder inhalers are derived from the commercially-validated AirFluSal® Gyrohaler® platform, but with a range of user interfaces and payload volumes, giving you confidence of performance and a proven regulatory track record.

With options for proprietary unit- and multi-unit dose platforms, as well as off-the-shelf capsule devices, we can support your programme from early development through to a commercial-ready device.

Our state-of-the-art breath-actuated nebulisers with guided inhalation have been developed to improve lung delivery for inhaled drugs, with the aim of achieving better clinical outcomes and/or shortened treatment times.

FOX® nebuliser: handheld system that delivers high performance using a vibrating mesh technology. FOX® is suitable for the delivery of small molecules and biologics, formulated as solutions or nano-suspensions. The device has a 510(k) premarket notification for marketing in the US. 

AKITA® JET nebuliser: desktop system which uses proprietary positive pressure technology to assist drug delivery to the lungs. Potential as multi-patient device in hospital setting. The device is CE-marked and has a 510(k) premarket notification for marketing in the US.

From one-off studies and specialist techniques through to full development services, our inhalation services can support your programme through all stages of clinical development and get your product ready for commercial manufacturing.

We understand different customers may require different types of collaborations. You may be working in a biotech company with an early-phase molecule, looking for fast progression to the clinic and proof-of-concept, or you may be part of a large pharmaceutical company trying to overcome a technical challenge, or looking for a solution to de-risk your programme.

With over 20 years’ experience in inhaled product development, and a track record of helping customers, partners and licensees succeed in bringing inhaled medicines to market, you can trust us with your product candidate.

Explore the series of Learning Labs at CPhI North America in which thought leaders at our exhibitors showcase their extensive knowledge on all areas of the pharma supply chain, offering industry insights across drug manufacturing, outsourcing, pharma ingredients, drug delivery and packaging.

Exploring the many factors which contribute to the success of pMDI, DPI and nebuliser development programmes

IHL-216A may make sports safer and reduce the morbidity and mortality rates of people suffering serious head traumas

Strategies to accelerate inhaled drug development including technology platform selection.

The enhancements will include installing the lever-operated multi-dose inhaler device used in Hikma’s generic Advair product, which the FDA recently approved

Vectura Dry Powder Inhaler (DPI) services and capabilities

The expansion will enable the CDMO to widen the nature of inhaled drug development projects it can undertake for customers

The future commercial success of any new inhaled medicine relies in a large part on the correct combination of formulation and device technology chosen for its delivery. This presentation will benefit any drug developer considering an inhaled programme and aims to answer the following questions: How are development targets and success criteria set for inhaled products? What are the key factors influencing inhaled delivery platform selection? How can phase-appropriate device selection accelerate an inhaled development programme? This session was originally broadcast live as part of CPhI North America 2021

Download a summary of Vectura's services and capabilities

This article discusses how delivery technology can help customers develop existing drugs for inhaled use, as well as highlighting the key challenges and opportunities faced during inhaled product development.

Interested in the critical success factors for an inhaled development programme? Download this article which discusses inhaled delivery platform selection and strategies to accelerate development timelines and reduce risk.

Download this free webcast where Dr Sandy Munro, SVP Pharmaceutical Development, discusses strategies to progress inhaled products quickly to clinical stages of development.

Vectura inhaled formulation, device and development services